Adagene shares up 10.28% intraday after Guggenheim raises price target to $10 with maintained Buy rating.

Adagene surged 10.28% intraday following Guggenheim’s upgrade of its price target from $9 to $10, while maintaining a Buy rating. The firm cited updated FY25 modeling as a key factor behind the adjustment. The repeated nature of the news across multiple outlets highlights the significance of the analyst action, which is typically viewed as a catalyst for short-term share momentum. The upgrade signaled improved confidence in Adagene’s outlook, aligning with the stock’s sharp intraday increase.